Jonathan R. Strosberg

Jonathan R. Strosberg, MD is Associate Member in Gastrointestinal Oncology and Director of the Neuroendocrine Tumor Program at Moffitt Cancer Center. He is internationally recognized as the principal investigator of the NETTER-1 trial, the landmark phase III study that established lutetium-177 DOTATATE (Lutathera) peptide receptor radionuclide therapy (PRRT) as a new standard of care for advanced midgut NETs, leading to the first FDA approval of PRRT in the United States in 2018. His research encompasses novel therapeutic strategies, biomarker discovery, and optimization of PRRT combinations in NETs. Beyond NETTER-1, Dr. Strosberg has led multiple investigator-initiated and cooperative group trials in NETs, including studies of combination PRRT plus chemotherapy and novel radioligand strategies. His translational work has characterized somatostatin receptor expression, tumor heterogeneity, and mechanisms of PRRT resistance. He has also contributed to international consensus guidelines for PRRT patient selection and dosimetry. A highly sought-after speaker at ASCO, ESMO, and the European Neuroendocrine Tumor Society (ENETS), Dr. Strosberg has authored over 200 peer-reviewed publications and is a leading advocate for nuclear medicine integration into oncology practice. He serves on the editorial boards of multiple high-impact oncology journals.